parkinsons disease pd simply parkinsons chronic degenerative disorder central nervous system affects motor system nonmotor systems symptoms usually emerge slowly disease progresses nonmotor symptoms become common early symptoms tremor rigidity slowness movement difficulty walking problems may also arise cognition behaviour sleep sensory systems parkinsons disease dementia common advanced stages motor symptoms disease result nerve cell death substantia nigra midbrain region supplies dopamine basal ganglia cause cell death poorly understood involves aggregation protein alphasynuclein lewy bodies within neurons collectively main motor symptoms known parkinsonism contributing factors include combination genetic environmental factors affected family member increased risk getting disease certain genes known inheritable risk factors environmental risks include exposure pesticides prior head injuries history exposure trichloroethylene also suspected diagnosis parkinsons disease mainly based symptoms usually motorrelated pd typically occurs people age one percent affected younger termed earlyonset pd average postdiagnosis life expectancy years cure pd known treatment aims mitigate symptoms initial treatment typically includes ldopa maob inhibitors dopamine agonists disease progresses medications become less effective produce side effect marked involuntary muscle movements diet certain forms rehabilitation shown effectiveness improving symptoms surgery place microelectrodes deep brain stimulation used reduce severe motor symptoms drugs ineffective evidence treatments nonmovementrelated symptoms pd sleep disturbances emotional problems less strong disease named english doctor james parkinson published first detailed description essay shaking palsy public awareness campaigns include world parkinsons day use red tulip symbolizes parkinsons awareness people pd increased publics awareness condition include boxer muhammad ali actor michael j fox progressive neurodegenerative parkinsons disease pd common form encompasses tremor bradykinesia rigidity postural also called idiopathic parkinsonism meaning identifiable parkinsons classified ways parkinsonian syndromes include parkinsons along included among lewy body synucleinopathy meaning characterized abnormal deposits alphasynuclein protein brain synucleinopathies include dementia lewy bodies multiple system atrophy rarer rare genetic forms parkinsons exhibit alphasynuclein recognizable symptoms movement motor related include tremor bradykinesia slowness movement rigidity shufflingstooped nonmotor symptoms including autonomic dysfunction dysautonomia neuropsychiatric problems mood cognition behavior thought alterations sensory especially altered sense smell sleep difficulties may present well people parkinsons disease may nonmotor symptoms precede onset motor symptoms including constipation anosmia rem behavior disorder generally symptoms dementia psychosis orthostasis severe falls occur dysphagia begin time course parkinsons affects patientsbetter source four motor symptoms considered cardinal signs pd tremor slowness movement bradykinesia rigidity postural common presenting sign coarse slow tremor hand rest disappears voluntary movement affected arm deeper stages typically appears one hand eventually affecting hands disease frequency pd tremor hertz cycles per second common characteristic tremor pillrolling tendency index finger thumb touch perform together circular term derives similarity movement people pd early pharmaceutical technique manually making bradykinesia due disturbances motor planning movement initiation associated difficulties along whole course movement process planning initiation execution movement performance sequential simultaneous movement impaired bradykinesia handicapping symptom parkinsons disease presenting difficulties everyday tasks dressing feeding bathing leads particular difficulty carrying two independent motor activities time made worse emotional stress concurrent illnesses paradoxically people pd ride bicycle climb stairs easily walk level although physicians may readily notice bradykinesia formal assessment requires persons repetitive movements fingers parkinsonism rigidity hypokinesia uniform known leadpipe rigidity ratcheted known cogwheel combination tremor increased tone considered origin cogwheel rigidity may associated joint pain pain frequent initial manifestation early stages pd rigidity asymmetrical tends affect neck shoulder muscles muscles face progression disease rigidity typically affects whole body reduces ability move postural instability typical later stages disease leading impaired balance frequent secondarily bone fractures loss confidence reduced instability absent initial stages especially younger people especially development bilateral people diagnosed pd may experience falls around may falls weekly number falls related severity recognized motor signs symptoms include gait posture disturbances festination rapid shuffling steps forwardflexed posture walking flexed arm swing common signs include freezing gait brief arrests feet seem get stuck floor especially turning changing direction slurred monotonous quiet voice masklike facial expression handwriting gets smaller although individuals pd typically motor symptoms predominantly one side body masklike facial expression occur sides pd causes neuropsychiatric disturbances ranging mild severe including disorders cognition mood behavior cognitive disturbances occur early stages diagnosis increase prevalence duration common cognitive deficit executive dysfunction include problems planning cognitive flexibility abstract thinking rule acquisition inhibiting inappropriate actions initiating appropriate actions working memory control cognitive difficulties include slowed cognitive processing speed impaired recall impaired perception estimation nevertheless improvement appears recall aided visuospatial difficulties part disease seen example individual asked perform tests facial recognition perception orientation drawn psychosis considered symptom prevalence hallucinations delusions occur people pd course illness may herald emergence dementia range minor hallucinations sense passage something quickly passing beside person sense presence perception something someone standing side behind person full blown vivid formed visual hallucinations paranoid ideation auditory hallucinations uncommon pd rarely described voices psychosis believed integral part disease psychosis delusions associated delirium recognized complication antiparkinson drug treatment urinary tract infections frequent elderly underlying brain pathology changes neurotransmitters receptors eg acetylcholine serotonin thought play role psychosis behavior mood alterations common pd without cognitive impairment general population usually present pd dementia frequent mood difficulties depression apathy depression impacts estimated patients may appear stage disease manifest symptoms common disease process fatigue insomnia difficulty concentration makes diagnosis difficult imbalance changes dopamine serotonin noradrenergic hormones functional impairment causes depression pdaffected suicidal ideation higher general population suicidal attempts risk factors depression include disease onset age female previous history depression severe motor anxiety estimated prevalence pdaffected people usually around anxiety pd complex consists symptoms specific needed anxiety higher motor periods times medication ineffective likely diagnosed diagnosis due dysfunction neurotransmitter needed pdaffected people experience panic attacks frequently compared general population anxiety depression found associated decreased quality symptoms range mild episodic chronic potential causes abnormal gammaaminobutyric acid levels embarrassment fear symptoms risk factors anxiety pd disease onset age women apathy anhedonia defined loss motivation impaired ability experience symptoms classically associated depression differ pdaffected people treatment mechanism apathy presents around symptoms apathy include reduced initiativeinterests new activities world around emotional indifference loss affection concern apathy associated deficits cognitive functions including executive verbal anhedonia occurs people pd depending study population assessed overlap impulsecontrol disorders including pathological gambling compulsive sexual behavior binge eating compulsive shopping reckless generosity medicationrelated particularly orally active dopamine agonists dopamine dysregulation syndrome wanting medication contributing overuse rare complication levodopa gastrointestinal issues parkinsons disease include constipation impaired stomach emptying gastric dysmotility excessive production saliva severe enough cause discomfort endanger upper gastrointestinal symptoms include swallowing impairment oropharyngeal dysphagia small intestinal bacterial individuals parkinsons alphasynuclein deposits digestive tract well constipation one symptoms associated increased risk pd may precede diagnosis sleep disorders occur pd worsened symptoms manifest daytime drowsiness including sudden sleep attacks resembling narcolepsy disturbances rapid eye movement sleep rem behavior disorder may begin years development motor cognitive elements pd dementia lewy alterations autonomic nervous system lead orthostatic hypotension low blood pressure standing oily skin excessive sweating urinary incontinence altered sexual changes perception may include impaired sense smell disturbed vision pain paresthesia tingling symptoms occur years diagnosis none proposed risk factors conclusively frequently replicated relationships increased risk exposed pesticides reduced risk research indicates pd results complex interaction genetic environmental small minority cases attributed solely genetic causes moreover idiopathic pd last progress decades timing exposure factor may influence progression severity certain statistically significant geographical clusters parkinsons cases reported suggesting common environmental cause either chemical infectiousbetter source research indicates pd results complex interaction genetic environmental around diagnosed individuals firstdegree relative mutation harboring one gene mutations may lead disease susceptibility factors put increased risk combination factors affect age onset severity least autosomal dominant nine autosomal recessive gene mutations implicated development pd autosomal dominant genes include snca autosomal recessive genes include prkn genes xlinked unknown inheritance pattern include deletion known associated autosomal dominant form associated mutations people pd mutations mutations present fewer unaffected population risk developing pd increased mutations present pd associated mutations clinical presentation earlier age onset rapid cognitive motor decline gene encodes glucocerebrosidase low levels enzyme cause gauchers diseasecitation needed alphasynuclein protein encoded snca gene mutations main component lewy bodies accumulate brains people alphasynuclein activates ataxia telangiectasia mutated major dna damagerepair signaling addition alphasynuclein activates nonhomologous end joining dna repair pathway aggregation alphasynuclein lewy bodies appears link reduced dna repair braincell death mutations genes including snca gba found risk factors sporadic nonfamilial mutations gene common known cause familial sporadic pd accounting around individuals family history disease sporadic mutation gba presents greatest genetic risk developing parkinsons parkinsonrelated genes involved function lysosomes organelles digest cellular waste products lysosomal disorders reduce ability cells break alphasynuclein may cause multidecade studies identified increased likelihood parkinsons association agricultural work pesticide exposure rural habitation chlorinated solvents used commercial industrial application like dry cleaning degreasing associated increased pd risk particularly manganese induced parkinsonslike pathology mice also associated higher risk welders higher pd risk tentatively manganese fumes exposure suspended particles traffic fumes also associated exposure heavy metals mercury lead may play medical drugs implicated parkinsonismdruginduced parkinsonism normally reversible stopping offending phenothiazines butyrophenones metoclopramide tetrabenazine drug known causing irreversible parkinsonism commonly used animalmodel low concentrations urate blood associated increased traumatic brain injuries tbis strongly implicated risk factors although association may distorted due recall bias sampling bias retrospective possibly due recurrent head impacts playing american football longer period higher levels associated higher pd veterans also higher risk proposed mechanisms tbis could induce accelerate parkinsons include alphasynuclein accumulation inflammation metabolic vascular parkinsonism phenomenon presence parkinsons disease symptoms combined findings vascular events cerebral stroke damaging dopaminergic pathways similar cause vascular parkinsonism idiopathic pd present similar symptoms differentiation made careful bedside examination history evaluation possible link exists pd helicobacter pylori infection prevent absorption drugs including behavioral psychological factors also associated risk pd example metaanalysis found neuroticism associated higher risk incident similarly sample half million individuals found adults reported lonely greater risk developing pd years main pathological characteristics pd cell death brains basal ganglia affecting dopaminesecreting neurons substantia nigra pars compacta end parkinsons disease alphasynuclein becomes misfolded clump together alphasynuclein cells unable remove clumps alphasynuclein becomes cytotoxic damaging clumps seen neurons microscope called lewy bodies loss neurons accompanied death astrocytes starshaped glial cells increase number microglia another type glial cell substantia needed severity progression parts brain affected pd measured braak staging according staging pd starts medulla olfactory bulb moving substantia nigra pars compacta rest midbrainbasal forebrain movement symptom onset associated disease begins affect substantia nigra pars five major pathways brain connect brain areas basal ganglia known motor oculomotor associative limbic orbitofrontal circuits names indicate main projection area affected pd disruption causes movement attention learningrelated symptoms scientifically motor circuit examined since particular conceptual model motor circuit alteration pd influence although limitations pointed led model basal ganglia normally exert constant inhibitory influence wide range motor systems preventing becoming active inappropriate times decision made perform particular action inhibition reduced required motor system thereby releasing activation dopamine acts facilitate release inhibition high levels dopamine function tend promote motor activity low levels dopamine function occur pd demand greater exertions effort given movement result dopamine depletion produce hypokinesia overall reduction motor drugs used treat pd conversely may produce excessive dopamine activity allowing motor systems activated inappropriate times thereby producing one mechanism causing brain cell death results abnormal accumulation protein alphasynuclein bound ubiquitin damaged cells insoluble protein accumulates inside neurons forming inclusions known lewy bodies first appear olfactory bulb medulla oblongata pontine tegmentum individuals stage may asymptomatic early nonmotor symptoms loss sense smell sleep automatic dysfunction disease progresses lewy bodies develop substantia nigra areas midbrain basal forebrain finally brain sites main places neuronal degeneration pd lewy bodies may protective cell death abnormal protein sequestered walled forms alphasynuclein eg oligomers aggregated lewy bodies lewy neurites may fact toxic forms people dementia generalized presence lewy bodies common cortical areas neurofibrillary tangles senile plaques characteristic alzheimers disease uncommon unless person needed mechanisms include proteasomal lysosomal systems dysfunction reduced mitochondrial iron accumulation substantia nigra typically observed conjunction protein inclusions may related oxidative stress protein aggregation neuronal death mechanisms neuroimmune interaction heavily implicated pd pathology pd autoimmune disorders share genetic variations molecular pathways autoimmune diseases may even increase ones risk developing pd one autoimmune diseases linked protein expression profiles monocytes cells linked pd herpes virus infections trigger autoimmune reactions alphasynuclein perhaps molecular mimicry viral alphasynuclein aggregate form lewy bodies bind microglia microglia proliferate overactivated alphasynuclein binding mhc receptors inflammasomes bringing release proinflammatory cytokines like ifnγ activated microglia influence activation astrocytes converting neuroprotective phenotype neurotoxic one astrocytes healthy brains serve protect neuronal connections parkinsons disease astrocytes protect dopaminergic connections striatum microglia present antigens via mhci mhcii cells cells activated process able cross blood brain barrier bbb release proinflammatory cytokines like interferonγ ifnγ tnfα mast cell degranulation subsequent proinflammatory cytokine release implicated bbb breakdown pd another immune cell implicated pd peripheral monocytes found substantia nigra people pd monocytes lead dopaminergic connection breakdown addition monocytes isolated people parkinsons disease express higher levels pdassociated protein compared nonpd individuals via addition high levels proinflammatory cytokines lead production creactive protein liver another protein commonly found people pd lead increase peripheral peripheral inflammation affect gutbrain axis area body highly implicated pd people pd altered gut microbiota colon problems years motor issues alphasynuclein produced gut may migrate via vagus nerve brainstem substantia nigraundue weight discussbetter source physicians initial assessment typically based medical history neurological assess motor symptoms bradykinesia rest tremors etc using clinical diagnostic criteria finding lewy bodies midbrain autopsy usually considered final proof person pd clinical course illness time may diverge pd requiring presentation periodically reviewed confirm accuracy multiple causes occur parkinsonism diseases look similar stroke certain medications toxins cause secondary parkinsonism need assessed parkinsonplus syndromes progressive supranuclear palsy multiple system atrophy must considered ruled appropriately begin different treatment disease progression antiparkinsons medications typically less effective controlling symptoms parkinsonplus faster progression rates early cognitive dysfunction postural instability minimal tremor symmetry onset may indicate parkinsonplus disease rather pd medical organizations created diagnostic criteria ease standardize diagnostic process especially early stages disease widely known criteria come uk queen square brain bank neurological disorders us national institute neurological disorders stroke queen square brain bank criteria require slowness movement bradykinesia plus either rigidity resting tremor postural instability possible causes symptoms need ruled finally three following supportive symptoms required onset evolution unilateral onset tremor rest progression time asymmetry motor symptoms response levodopa least five years clinical course least ten years appearance dyskinesias induced intake excessive assessment sudomotor function electrochemical skin conductance helpful diagnosing pd diagnoses checked autopsy movement disorders experts found average accurate initial assessment accurate refining diagnoses followup examinations clinical diagnoses performed mainly nonexperts checked autopsy average accuracy overall pd diagnoses accurate diagnoses using brain bank criteria computed tomography ct scans people pd usually appear magnetic resonance imaging become accurate diagnosis disease time specifically ironsensitive susceptibility weighted imaging sequences magnetic field strength least demonstrate absence characteristic swallow tail imaging pattern dorsolateral substantia metaanalysis absence pattern highly sensitive specific metaanalysis found neuromelaninmri discriminate individuals parkinsons healthy diffusion mri shown potential distinguishing pd parkinsonplus syndromes well pd motor though diagnostic value still ct mri used rule diseases secondary causes parkinsonism commonly encephalitis chronic ischemic insults well lessfrequent entities basal ganglia tumors metabolic activity dopamine transporters basal ganglia directly measured positron emission tomography singlephoton emission computed tomography scans shown high agreement clinical diagnoses reduced dopaminerelated activity basal ganglia help exclude druginduced parkinsonism finding nonspecific seen pd parkinsonplus united states datscans fda approved distinguish pd parkinsonian syndromes essential myocardial scintigraphy help locate denervation muscles heart support pd secondary parkinsonism multiple causes parkinsonism differentiated careful history physical examination appropriate parkinsonplus syndromes similar movement symptoms variety associated symptoms also synucleinopathies lewy body dementia involves motor symptoms early onset cognitive dysfunction hallucinations precede motor symptoms alternatively multiple systems atrophy msa usually early onset autonomic dysfunction orthostasis may autonomic predominance cerebellar symptom predominance parkinsonian parkinsonplus syndromes involve tau rather alphasynuclein include progressive supranuclear palsy psp corticobasal syndrome cbs psp predominantly involves rigidity early falls bulbar symptoms vertical gaze restriction associated frontotemporal dementia symptoms cbs involves asymmetric parkinsonism dystonia alien limb myoclonic presentation timelines associated symptoms help differentiate similar movement disorders idiopathic parkinson diseasemedical citation needed parkinsonplus syndrome multiple diseases considered part parkinsons plus group including corticobasal syndrome multiple system atrophy progressive supranuclear palsy dementia lewy bodies differential diagnosis narrowed careful history physical exam especially focused sequential onset specific symptoms progression disease response key conditions similar presentations pd exercise middle age may reduce risk pd later caffeine appears protective greater decrease risk occurring larger intake caffeinated beverages antioxidants vitamins c e proposed protect disease results studies contradictory positive effect results regarding fat fatty acids use nonsteroidal antiinflammatory drugs nsaids calcium channel blockers may metaanalysis found nsaids apart aspirin associated least higher longterm regular users reduction incidence development metaanalyses failed confirm link multiple studies demonstrated link use ibuprofen decreased risk parkinsons cure parkinsons disease known medications surgery physical treatment may provide relief improve quality persons life much effective treatments neurological disorders alzheimers disease motor neuron disease parkinsonplus main families drugs useful treating motor symptoms levodopa always combined dopa decarboxylase inhibitor comt inhibitor dopamine agonists maob inhibitors stage disease age disease onset determine group braak staging pd uses six stages identify early middle late initial stage disability already developed requires pharmacological treatment followed later stages associated development complications related levodopa usage third stage symptoms unrelated dopamine deficiency levodopa treatment may treatment first stage aims optimal tradeoff symptom control treatment side effects start levodopa treatment may postponed initially using medications maob inhibitors dopamine agonists instead hope delaying onset complications due levodopa levodopa still effective treatment motor symptoms pd treatment prompt people quality life impaired levodoparelated dyskinesias correlate strongly duration severity disease duration levodopa later stages aim reduce pd symptoms controlling fluctuations effect medication sudden withdrawals medication overuse must oral medications inadequate controlling symptoms surgery deep brain stimulation highintensity focused subcutaneous wakingday apomorphine infusion enteral dopa pumps may latestage pd presents challenges requiring variety treatments including psychiatric symptoms particularly depression orthostatic hypotension bladder dysfunction erectile final stages disease palliative care provided improve persons quality cochrane review found certain evidence cognitive training beneficial people parkinsons disease dementia mild cognitive findings based low certainty evidence seven studies standard treatment pdassociated anxiety needed levodopa usually first drug choice treating parkinsons disease widely used pd treatment since motor symptoms pd result reduced dopamine production brains basal ganglia dopamine fails cross barrier taken medicine boost brains depleted levels dopamine precursor dopamine levodopa pass brain readily converted dopamine administration levodopa temporarily diminishes motor symptoms pd levodopa crosses barrier much remainder metabolized dopamine elsewhere body causing variety sideeffects including nausea vomiting orthostatic carbidopa benserazide dopa decarboxylase inhibitors fail cross barrier inhibit conversion levodopa dopamine outside brain reducing sideeffects improving availability levodopa passage brain one drugs usually taken along levodopa available combined levodopa prolonged use levodopa associated development complications involuntary movements dyskinesias fluctuations impact fluctuations occur person cycle phases good response medication reduced pd symptoms state phases poor response medication increased pd symptoms using lower doses levodopa may reduce risk severity levodopainduced former strategy called drug holidays reduce levodoparelated dyskinesia fluctuations withdraw levodopa medication bring dangerous sideeffects neuroleptic malignant syndrome people pd eventually need levodopa later develop levodopainduced fluctuations adverse effects levodopa including dyskinesias may mistakenly influence people affected disease sometimes healthcare professionals delay treatment reduces potential optimal resultsmedical citation needed levodopa available oral inhalation infusion form inhaled levodopa used oral levodopa therapy reached point periods increased course pd affected people experience wearingoff phenomenon recurrence symptoms occurs dose levodopa right next catecholomethyltransferase comt protein degrades levodopa cross barrier comt inhibitors allow levodopa normally used management later symptoms used conjunction levodopacarbidopa person experiencing wearing offphenomenon motor three comt inhibitors used treat adults pd endofdose motor fluctuations opicapone entacapone tolcapone available usefulness limited possible liver damage complications requiring liverfunction entacapone opicapone cause little alteration liver licensed preparations entacapone contain entacapone alone combination carbidopa opicapone oncedaily comt dopamine agonists bind dopamine receptors brain similar effects initially used complementary therapy levodopa individuals experiencing levodopa complications onoff fluctuations dyskinesias mainly used first therapy motor symptoms pd aim delaying initiation levodopa therapy thus delaying onset levodopas dopamine agonists include bromocriptine pergolide pramipexole ropinirole piribedil cabergoline apomorphine lisuride though dopamine agonists less effective levodopa controlling pd motor symptoms effective enough manage symptoms first years dyskinesias due dopamine agonists rare younger people pd along complications become common older age thus dopamine agonists preferred initial treatment youngeronset pd levodopa preferred olderonset dopamine agonists produce side effects including drowsiness hallucinations insomnia nausea side effects appear minimal clinically effective doses giving physician reason search different agonists related impulsecontrol disorders increased sexual activity eating gambling shopping strongly antiparkinson apomorphine dopamine agonist may used reduce periods dyskinesia late administered intermittent injections continuous subcutaneous secondary effects confusion hallucinations common individuals receiving apomorphine treatment closely two dopamine agonists administered skin patches lisuride rotigotine useful people initial stages possibly control states advanced needed due increased risk cardiac fibrosis ergotderived dopamine agonists bromocriptine cabergoline dihydroergocryptine lisuride pergolide considered adjunct therapy maob inhibitors safinamide selegiline rasagiline increase amount dopamine basal ganglia inhibiting activity monoamine oxidase b enzyme breaks found help alleviate motor symptoms used monotherapy used conjunction levodopa time spent phase selegiline shown delay need beginning levodopa suggesting might neuroprotective slow progression initial study indicated selegiline combination levodopa increased risk death common side effects nausea dizziness insomnia sleepiness selegiline rasagiline orthostatic maobs known increase serotonin cause potentially dangerous condition known serotonin drugs amantadine may useful treatment motor symptoms evidence use anticholinergics used dyskinesia motor fluctuations may considered topically diverse range symptoms beyond related motor function treated examples use quetiapine clozapine psychosis cholinesterase inhibitors memantine dementia modafinil excessive daytime pimavanserin approved management pd doxepin rasagline may reduce physical fatigue treating motor symptoms surgery common practice discovery levodopa decreased amount studies led great improvements surgical techniques surgery used people advanced pd drug therapy longer surgery pd divided two main groups lesional deep brain stimulation dbs target areas dbs lesions include thalamus globus pallidus subthalamic dbs involves implantation medical device called neurostimulator sends electrical impulses specific parts brain dbs recommended people pd motor fluctuations tremor inadequately controlled medication intolerant medication lacking severe neuropsychiatric less common surgical therapies involve intentional formation lesions suppress overactivity specific subcortical areas example pallidotomy involves surgical destruction globus pallidus control four areas brain treated neural stimulators globus pallidus interna thalamus subthalamic nucleus pedunculopontine nucleus dbs globus pallidus interna improves motor function dbs thalamic dbs improves tremor little impact bradykinesia rigidity dbs subthalamic nucleus usually avoided history depression neurocognitive impairment present dbs subthalamic nucleus associated reduction medication pedunculopontine nucleus dbs remains experimental present generally dbs associated improvement motor score exercise programs recommended people evidence shows speech mobility problems improve rehabilitation although studies scarce low regular physical exercise without physical therapy beneficial maintain improve mobility flexibility strength gait speed quality exercise program performed supervision physiotherapist improvements occur motor symptoms mental emotional functions daily living activities quality life compared selfsupervised exercise program clinical exercises may effective intervention targeting overall wellbeing individuals parkinsons improvement motor function depression may improving flexibility range motion people experiencing rigidity generalized relaxation techniques gentle rocking found decrease excessive muscle tension effective techniques promote relaxation include slow rotational movements extremities trunk rhythmic initiation diaphragmatic breathing meditation gait addressing challenges associated disease hypokinesia shuffling decreased arm swing physiotherapists variety strategies improve functional mobility safety areas interest concerning gait rehabilitation programs focus improving gait speed base support stride length trunk armswing movement strategies include using assistive equipment pole walking treadmill walking verbal cueing manual visual auditory exercises marching pnf patterns altering environments surfaces inputs open vs strengthening exercises shown improvements strength motor function people primary muscular weakness weakness related inactivity mild moderate pd reports show interaction strength time medications taken therefore people pd perform exercises minutes one hour medications deep diaphragmatic breathing exercises beneficial improving chestwall mobility vital capacity decreased forward flexed posture respiratory dysfunctions advanced exercise may improve whether exercise reduces physical fatigue pd remains strength training exercise shown increase manual dexterity people pd exercising manual putty improvements manual dexterity strength favorable impact people parkinsons disease fostering increased independence daily activities require grasping lee silverman voice treatment lsvt one widely practiced treatments speech disorders associated speech therapy specifically lsvt may improve occupational therapy ot aims promote health quality life helping people disease participate large percentage daily living studies conducted effectiveness ot quality poor although indication may improve motor skills quality life duration goal palliative care improve quality life patient family providing relief symptoms stress parkinsons uncurable treatments focus slowing decline improving quality life therefore palliative care involved earlier rather later disease palliative care specialists help physical symptoms emotional factors loss function jobs depression fear existential along offering emotional support affected person family palliative care addresses goals care people pd may difficult decisions make disease progresses wishes feeding tube noninvasive ventilator tracheostomy wishes cardiopulmonary resuscitation use hospice palliativecare team members help answer questions guide people pd complex emotional topics help make decisions based muscles nerves control digestive process may affected pd resulting constipation gastroparesis prolonged emptying stomach balanced diet based periodical nutritional assessments recommended designed avoid weight loss gain minimize consequences gastrointestinal disease advances swallowing difficulties dysphagia may appear using thickening agents liquid intake upright posture eating may useful measures reduce risk choking gastrostomy used deliver food directly levodopa proteins use transportation system intestine barrier thereby competing taking together results reduced effectiveness therefore levodopa introduced excessive protein consumption discouraged favour wellbalanced mediterranean diet advanced stages additional intake lowprotein products bread pasta recommended similar minimize interaction proteins levodopa taken minutes time regimens pd restrict proteins breakfast lunch allowing protein intake pd invariably progresses time severity rating method known unified parkinsons disease rating scale updrs commonly used metric clinical study modified version known mdsupdrs also used older scaling method known hoehn yahr scale originally published similar scale known modified hoehn yahr scale used hoehn yahr scale defines five basic stages progression motor symptoms may advance aggressively early stages disease slowly later untreated individuals expected lose independent ambulation average eight years bedridden years medication improved prognosis motor symptoms people taking levodopa progression time symptoms stage high dependency caregivers may years predicting course disease take given individual age appropriate predictor disease progression rate motor decline greater less impairment time diagnosis cognitive impairment frequent years age symptom hard correlation pd progression pd disability whole found however initial pd disability often mainly concerns motor symptoms whereas later stages often mainly related nonmotor symptoms disease therapies exist improve alleviate latter symptoms disease advances disability related motor symptoms uncontrollable medication difficulties swallowing dysartria gait balance problems levodopainduced complications appear individuals five years levodopa usage finally ten years people disease autonomic disturbances sleep problems mood alterations cognitive decline symptoms especially cognitive decline greatly increase life expectancy people pd reduced mortality ratios around twice unaffected people cognitive decline dementia old age onset advanced disease state presence swallowing problems mortality risk factors disease pattern mainly characterized tremor opposed rigidity though predicts improved survival death aspiration pneumonia twice common individuals pd healthy pd resulted deaths globally increase since overall death rate increased per people person pd two six times risk dementia compared general people pd parkinsons disease dementia associated reduced quality life people pd caregivers increased mortality higher probability needing nursing home pd second common neurodegenerative disorder alzheimers disease affects approximately seven million people globally one million people united proportion population given time industrialized countries pd common elderly rates rise years age population mean age onset around years although begin ages classified young onset males affected ratio around compared pd may less prevalent african asian ancestry although finding number new diagnoses per year pd per china predicted nearly half parkinsons disease population world number patients expected grow approximately million people growth referred parkinsons prevalence dementia increases age lesser degree duration early sources including egyptian papyrus ayurvedic medical treatise bible galens writings describe symptoms resembling galen references unambiguously related pd appear centuries franciscus sylvius hieronymus david gaubius john hunter auguste françois chomel wrote elements james parkinson published essay reporting six people paralysis essay shaking palsy described characteristic resting tremor abnormal posture gait paralysis diminished muscle strength way disease progresses early neurologists made additions knowledge disease include trousseau gowers kinnier wilson erb jeanmartin charcot whose studies increased understanding among advances charcot made distinction rigidity weakness championed renaming disease honor james frederic lewy described microscopic particles affected brains later named lewy konstantin tretiakoff reported substantia nigra main cerebral structure affected finding rejected confirmed studies published rolf hassler underlying biochemical changes brain identified due largely work arvid carlsson neurotransmitter dopamine oleh hornykiewicz role alphasynuclein found main component lewy bodies spillantini trojanowski goedert anticholinergics surgery lesioning corticospinal pathway basal ganglia structures treatments arrival levodopa reduced use levodopa first synthesized casimir funk received little attention mid entered clinical practice brought revolution management late deep brain stimulation introduced alim louis benabid colleagues grenoble france emerged possible illustration advanced parkinsons disease william richard gowers published manual diseases nervous system based photographs attributed albert new image created represent diversity levels people pd masked facial expressions difficulty moderating facial expressions emotion recognizing peoples facial expressions impact social condition progresses tremor motor symptoms difficulty communicating issues mobility may interfere social engagement causing individuals pd feel public perception awareness pd symptoms shaking hallucinating slurring speech balance lacking countries lead costs pd society high largest share direct cost came inpatient care nursing homes share coming medication substantially indirect costs high due reduced productivity burden addition economic costs pd reduces quality life disease study based data estimated us economic pd burden billion including direct medical costs billion billion indirect nonmedical costs projected total economic burden surpasses billion findings highlight need interventions reduce pd incidence delay disease progression alleviate symptom burden may reduce future economic burden birthday james parkinson april designated world parkinsons red tulip chosen international organizations symbol disease represents james parkinson tulip cultivar registered dutch advocacy organizations include national parkinson foundation provided million care research support services since parkinsons disease foundation distributed million research nearly million education advocacy programs since founding william american parkinson disease association founded european parkinsons disease association founded century diagnosis parkinsons among notable figures increased publics understanding actor michael j fox diagnosed pd years used diagnosis increase awareness illustrate effects disease fox appeared without medication television roles united states congress without michael j fox foundation founded raised billion parkinsons boxer muhammad ali showed signs pd undiagnosed called worlds famous parkinsons whether pd parkinsonism related boxing cyclist olympic medalist davis phinney diagnosed parkinsons started davis phinney foundation support pd deng xiaoping former paramount leader china advanced parkinsons time suicide robin williams american actor comedian diagnosed autopsy revealed dementia lewy bodies highlighting difficulties accurate diseasemodifying drugs drugs target causes damage approved parkinsons major focus parkinsons active research directions include search new animal models disease studies potential usefulness gene therapy stem cell transplants neuroprotective aid earlier diagnosis research criteria identifying prodromal biomarkers disease role axis gut flora pd recognized mechanism causes gastrointestinal symptoms gene therapy typically involves use noninfectious shuttle genetic material part brain approaches involved expression growth factors prevent damage neurturin gdnffamily growth factor enzymes glutamic acid decarboxylase gad enzyme produces gaba tyrosine hydroxylase enzyme produces ldopa catecholomethyl transferase comt enzyme converts ldopa dopamine safety concerns reported approaches largely failed phase two clinical delivery gad showed promise phase two trials effective improving motor function inferior dbs followup studies cohort suggested persistent vaccine primes human immune system destroy alphasynuclein entered clinical trials phase one report suggested safety antibody showed preliminary safety evidence stage trials supporting continuation stage ii beginning early fetal porcine carotid retinal tissues used cell transplants dissociated cells injected substantia nigra hope incorporate brain way replaces dopamineproducing cells sources tissues largely replaced induced pluripotent stem cell derived dopaminergic neurons thought represent feasible source tissue initial evidence showed mesencephalic dopamineproducing cell transplants beneficial longterm benefit additional problem excess release dopamine transplanted tissue resulting first human clinical trial reported transplantation induced pluripotent stem cells brain person antagonists adenosine receptors specifically explored istradefylline emerged successful medication approved medical use united states approved addon treatment levodopacarbidopa disease